Yokohama, Japan

Syunji Naruto

This inventor holds 2 USPTO granted patents. Top assignee: Sankyo Company, Limited. Active years: 1977-1999.


% Patents Active = 100.0

Average Co-Inventor Count = 5.5

ph-index = 2

Forward Citations = 9(Granted Patents)


Location History:

  • Tokyo, JA (1977)
  • Yokohama, JP (1999)

Company Filing History:


Years Active: 1977-1999

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Syunji Naruto: Innovator in Pharmaceutical Compounds

Introduction

Syunji Naruto is a notable inventor based in Yokohama, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that have therapeutic uses. With a total of 2 patents, his work focuses on innovative solutions for treating various medical conditions.

Latest Patents

Naruto's latest patents include groundbreaking research on heterocyclic compounds and their therapeutic applications. One of his notable inventions involves a compound of formula (I), which is effective in treating dementia, Alzheimer's disease, and delirium. This compound can also serve as a sedative. Another patent focuses on 2-aminoacetamido-α-phenylbenzylideneaminoalkanol derivatives, which are useful as minor tranquilizers. These derivatives can be synthesized by reacting the corresponding 2-amino-α-phenylbenzylideneaminoalkanol derivative with an aminocarboxylic acid.

Career Highlights

Syunji Naruto is associated with Sankyo Company, Limited, where he continues to innovate in the pharmaceutical sector. His work has the potential to impact the treatment of neurological disorders significantly.

Collaborations

Naruto has collaborated with notable colleagues, including Nigel Birdsall and Sebastian Lazareno, to advance his research and development efforts.

Conclusion

Syunji Naruto's contributions to pharmaceutical innovations highlight his commitment to improving healthcare through effective treatments. His patents reflect a dedication to addressing critical medical challenges.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…